Posted by Michael Wonder on 01 Feb 2022
FDA approves prophylactic treatment with Vonvendi [von Willebrand factor (recombinant)] for adult patients living with severe type 3 von Willebrand disease
31 January 2022 - Vonvendi [von Willebrand factor (recombinant)] is the first and only treatment approved for routine prophylaxis to reduce the frequency of bleeding episodes in adults living with severe type 3 VWD receiving on-demand therapy.
Takeda today announced that the U.S. FDA approved Vonvendi [von Willebrand factor (recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe type 3 von Willebrand disease receiving on-demand therapy.
